Last reviewed · How we verify

ccIIV4 — Competitive Intelligence Brief

ccIIV4 (ccIIV4) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated influenza vaccine Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ccIIV4 (ccIIV4) — Vanderbilt University Medical Center. ccIIV4 is a cell-culture-derived inactivated influenza vaccine that stimulates immune responses against multiple influenza virus strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ccIIV4 TARGET ccIIV4 Vanderbilt University Medical Center marketed Inactivated influenza vaccine
Fluzone High-Dose vaccine Fluzone High-Dose vaccine Sanofi Pasteur, a Sanofi Company marketed inactivated influenza vaccine
Fluzone Quadrivalent Influenza Vaccine Fluzone Quadrivalent Influenza Vaccine Sanofi Pasteur, a Sanofi Company marketed inactivated influenza vaccine
Agriflu (TIV) Agriflu (TIV) Novartis marketed Inactivated influenza vaccine
Enzira® vaccine Enzira® vaccine Seqirus marketed Inactivated influenza vaccine
CSL Limited Influenza Vaccine CSL Limited Influenza Vaccine Seqirus marketed inactivated influenza vaccine
Fluad alone Fluad alone Korea University Guro Hospital marketed Inactivated influenza vaccine with adjuvant Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

  1. GlaxoSmithKline · 16 drugs in this class
  2. Seqirus · 5 drugs in this class
  3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
  4. Green Cross Corporation · 4 drugs in this class
  5. Novartis · 2 drugs in this class
  6. SK Chemicals Co., Ltd. · 2 drugs in this class
  7. Sanofi · 2 drugs in this class
  8. Hospital Israelita Albert Einstein · 2 drugs in this class
  9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
  10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ccIIV4 — Competitive Intelligence Brief. https://druglandscape.com/ci/cciiv4. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: